The Prognostic Value of Lactate is Different Among Septic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04155060|
Recruitment Status : Completed
First Posted : November 7, 2019
Last Update Posted : July 27, 2020
|Condition or disease|
|Sepsis Diabetes Mellitus|
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Early diagnosis of sepsis and identification of more severe sepsis is important to improve the outcomes .Therefore, reliable markers are required to early identify the high-risk patients.
Currently, lactate is widely applied as the marker for evaluating the severity of sepsis and for outcome predicting.Nevertheless, the value of lactate for predicting sepsis is still controversial.The reasons for the different cutoff value may be due to the fact that sepsis is a heterogeneous disease which has already been defined by a number of clinical, laboratory and radiologic criteria, rather than specific pathologic findings. Therefore, we hypothesized that the discrepancy clinical value of lactate may be resulted from the heterogeneous feature of sepsis.
DM affects lactate balance and raised baseline lactate. The objective of this study was to compare the different prognostic value of admission lactate for sepsis patients with or without DM.
|Study Type :||Observational|
|Actual Enrollment :||256 participants|
|Official Title:||The Prognostic Value of Lactate is Different Among Septic Patients With or Without Diabetes Mellitus|
|Actual Study Start Date :||April 1, 2017|
|Actual Primary Completion Date :||April 1, 2019|
|Actual Study Completion Date :||April 1, 2019|
DM group , non-DM group
Septic patients were divided into the DM group and non-DM group, based on their comorbidity
high lactate group,low lactate group
high lactate group (lactate > 2 mmol/L) and low lactate group (lactate ≤ 2 mmol/L), according to the admission lactate level.
- The primary outcome was 28-day mortality [ Time Frame: up to at least 28 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04155060
|180 Fenglin Road|
|Shanghai, Shanghai, China, 200032|